POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (4.18.2021, 2:35pm CEST, WHO):   U.S. 73,697    India 261,500    Brazil 85,774    France 34,218    Russia 8,632    The United Kingdom 2,206    Turkey 62,606    Italy 15,364    Germany 19,185    Poland 12,151    Argentina 29,472    Columbia 16,703    Mexico 4,504    Iran 21,321    Ukraine 10,282    Peru 7,988    Indonesia 5,041    South Africa 1,325    The Netherlands 8,336    Chile 8,037    Canada 9,346    Romania 3,474    Iraq 6,552    Philippines 11,081    Hungary 3,706    Pakistan 4,976    Bangladesh 3,473    Jordan 1,596    Serbia 2,583    Austria 2,591    Japan 4,611    Lebanon 1,695    United Arab Emirates 1,958    Bulgaria 1,076    Malaysia 2,331    Ecuador 2,193    Belarus 1,384    Greece 2,411    Palestine 1,618    Croatia 1,565    Azerbaijan 2,148    Bolivia 1,246    Tunisia 2,199    Kuwait 1,388    Paraguay 2,278    Ethiopia 3,682    Costa Rica 1,044    Guatemala 1,640    Venezuela 1,244    Bahrain 1,024    Uruguay 3,070    Kenya 2,068    Puerto Rico 1,635    Cuba 1,026    Thailand 1,767    China 36    Singapore 39    New Zealand 5    Australia 21    South Korea 672   

Zika vaccine works in early human trial

Staff Writer |
An experimental vaccine for the Zika virus has shown signs of success in an early human trial.

Article continues below

The vaccine safely produced Zika-specific antibodies in 100 percent of the people involved in the study.

"Zika virus continues to be a threat to people living in the Americas and the Caribbean," said study author Dr. Pablo Tebas, a professor of infectious diseases at the University of Pennsylvania in Philadelphia.

"With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika," he said.

The synthetic DNA-based Zika vaccine is known as GLS-5700. Unlike some vaccines that use weakened or killed versions of a virus, the experimental Zika vaccine contains synthetic DNA instructions that enable the immune system to neutralize the virus.

The vaccine was developed by Inovio Pharmaceuticals, GeneOne Life Science and The Wistar Institute.

"Synthetic DNA vaccines are an ideal approach for emerging infectious diseases like Zika," study co-author David Weiner said in a Wistar news release. He's director of the institute's Vaccine & Immunotherapy Center.

Weiner said this new generation of DNA vaccines has significant advantages. They can be designed and manufactured rapidly. They also appear to be highly predictable for the generation of immunity in humans.

Plus, these vaccines are more stable than most traditional vaccines, "making them exceptionally practical to distribute during outbreaks, especially in regions where resources are limited and we need to be able to respond quickly to curb an emerging epidemic," Weiner said.

The trial included 40 people. It was conducted in 2016 from August to September. The participants were divided into two groups that received two different doses of the vaccine when the study began.

The study volunteers received additional doses at four and 12 weeks. Each dosage was delivered with Cellectra, a device that produces small, electric currents that help the body produce an immune response to the vaccine.

Two weeks after receiving the final dose of the vaccine, all 40 of the people involved in the study developed Zika-specific antibodies, the study showed.

The researchers noted that 80 percent of the participants developed significant protection against the virus. None of the people had a negative reaction to the vaccine.

What to read next

Effectiveness of AIDS vaccine depends on genetics
Cases of Zika-linked birth defects dropped in Brazil
Study finds antibody that 'neutralizes' Zika virus